ARTA
FBRX icon

A.R.T. Advisors’s Forte Biosciences FBRX Stock Holding History

A.R.T. Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-85
Closed -$21K – 1449
2019
Q3 		$21K Buy
85
+40
+89% +$60.7K ﹤0.01% 1367
2019
Q2 		$114K Buy
+45
New +$133K 0.01% 1178

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

A.R.T. Advisors's FBRX Position: Q4 2019 in Review

A.R.T. Advisors sold out of Forte Biosciences (FBRX) in Q4 2019, closing a stake of 85 shares — an estimated $21K sold.

A.R.T. Advisors first reported a position in FBRX in Q2 2019 and held it in 2 quarters. The position peaked at $114K in Q2 2019. 51 funds tracked by Wall St. Rank hold FBRX as of Q4 2019.

  • A.R.T. Advisors reported no remaining Forte Biosciences position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 85 Forte Biosciences shares in Q4 2019, an estimated $21K.
  • A.R.T. Advisors first reported a position in Forte Biosciences in Q2 2019 and held it in 2 quarters.
  • A.R.T. Advisors's Forte Biosciences position peaked at $114K in Q2 2019.
  • 51 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.